Suzano (SUZB3) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
11 Feb, 2026Executive summary
Achieved record sales and shipment volumes in pulp and paper for 2025, with pulp up 4% and paper up 10% year-over-year in 4Q25, driven by operational excellence, supply chain performance, and new operations.
Operational efficiencies and the Ribas do Rio Pardo operation contributed to the lowest cash production cost since 2021.
Strategic initiatives included the acquisition of a 51% stake in a global JV with Kimberly-Clark and the integration of US paperboard assets.
Ceased operations at the high-cost Rio Verde Mill to improve cost competitiveness.
Paper and packaging business delivered strong volumes in Brazil and the U.S., with improvements at Pine Bluff and Limeira mills.
Financial highlights
Generated $400 million in free cash flow in Q4 2025, reducing net debt to $12.6 billion and leverage to 3.2x.
Adjusted EBITDA for 2025 was R$21.7 billion, with Q4 EBITDA at R$5.6 billion and margin at 43%.
Achieved lowest cash cost since Q4 2021 at BRL 778/ton, a 3% reduction from Q3 2025.
Paid BRL 1.4 billion in dividends and completed a 15 million share buyback; new program for up to 40 million shares announced.
Liquidity increased to US$6.6 billion, with cash and equivalents plus stand-by facilities totaling R$32.4 billion.
Outlook and guidance
Expect lower sales volumes in Q1 2026 due to seasonality, but anticipate price improvements from announced increases.
Cash production cost of pulp in 2026 expected to remain broadly in line with Q4 2025 levels.
2026 CAPEX guidance reduced by nearly 20% year-on-year, with a capital budget of R$10.9 billion.
JV with Kimberly-Clark progressing as planned, with closing expected mid-2026.
Focus remains on reducing operational disbursement and net debt, supporting a declining cost trend toward 2027.
Latest events from Suzano
- EBITDA up 60% year-over-year, but net loss of R$3.77B on FX and derivative impacts.SUZB3
Q2 20241 Feb 2026 - EBITDA and sales volumes surged, with Ribas ramp-up and acquisitions boosting performance.SUZB3
Q3 202418 Jan 2026 - Cost leadership, operational excellence, and disciplined capital allocation drive growth.SUZB3
Investor Day 202411 Jan 2026 - Record sales and EBITDA driven by Ribas ramp-up, but FX losses led to a net loss.SUZB3
Q4 20248 Jan 2026 - Focus is on competitiveness, cost reduction, and disciplined growth amid market shifts.SUZB3
Investor Day 202512 Dec 2025 - Strong sales growth, robust cash flow, and major strategic moves marked the quarter.SUZB3
Q2 202523 Nov 2025 - Net income rose to R$6.3B in 1Q25, with stable leverage and strong free cash flow.SUZB3
Q1 202518 Nov 2025 - JV creates a global tissue leader with $3.3bn revenue, $175M synergies, and strong diversification.SUZB3
Investor Update12 Nov 2025 - Cash cost below BRL 800/ton, EBITDA down 20%, leverage up, 2025 capex guidance reaffirmed.SUZB3
Q3 20257 Nov 2025